DDInter542 DDInter707
Dicoumarol is an oral anticoagulant agent that works by interfering with the metabolism of vitamin K. In addition to its clinical use, it is also used in biochemical experiments as an inhibitor of reductases.
Ezetimibe is a lipid-lowering compound that inhibits intestinal cholesterol and phytosterol absorption. The discovery and research of this drug began in the early 1990s, after the intravenous administration of radiolabelled ezetimibe in rats revealed that it was being localized within enterocytes of the intestinal villi - this prompted studies investigating the effect of ezetimibe on intestinal cholesterol absorption. Ezetimibe is used as an adjunctive therapy to a healthy diet to lower cholesterol levels in primary hyperlipidemia, mixed hyperlipidemia, homozygous familial hypercholesterolemia (HoFH), and homozygous sitosterolemia (phytosterolemia). Unlike other classes of cholesterol-reducing compounds including statins and bile acid sequestrants, ezetimibe has a distinct mechanism of action involving the sterol transporter Niemann-Pick C1-Like 1 (NPC1L1), and is unique in that it does not affect the absorption of fat-soluble nutrients such as fat-soluble vitamins, triglycerides, or bile acids. In genetically NPC1L1-deficient mice, a 70% reduction in intestinal cholesterol absorption was seen, and these mice were insensitive to ezetimibe treatment - it was determined based on these findings that NPC1L1 plays an essential role in promoting intestinal cholesterol uptake via an ezetimibe-sensitive pathway. By interfering with the intestinal uptake of cholesterol and phytosterols, ezetimibe reduces the delivery of intestinal cholesterol to the liver.
Dicoumarol {u} (Compound) resembles {v} (Compound) Warfarin
Warfarin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ezetimibe
Dicoumarol {u} (Compound) resembles {v} (Compound) Phenprocoumon
Phenprocoumon {u} (Compound) resembles {v} (Compound) Warfarin
Warfarin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ezetimibe
Dicoumarol {u} (Compound) resembles {v} (Compound) Warfarin
Warfarin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ezetimibe
Dicoumarol {u} (Compound) resembles {v} (Compound) Warfarin
Warfarin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rosuvastatin
Rosuvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ezetimibe
Dicoumarol {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Simvastatin
Simvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ezetimibe
Dicoumarol {u} (Compound) binds {v} (Gene) NQO1
NQO1 {u} (Gene) regulates {v} (Gene) TM9SF3
TM9SF3 {u} (Gene) is downregulated by {v} (Compound) Ezetimibe
Dicoumarol {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Flunarizine
Flunarizine {u} (Compound) resembles {v} (Compound) Ezetimibe
Dicoumarol {u} (Compound) resembles {v} (Compound) Acenocoumarol
Acenocoumarol {u} (Compound) causes {v} (Side Effect) Decreased appetite
Decreased appetite {u} (Side Effect) is caused by {v} (Compound) Ezetimibe
Dicoumarol {u} (Compound) binds {v} (Gene) NQO1
NQO1 {u} (Gene) regulates {v} (Gene) DDIT4
DDIT4 {u} (Gene) is upregulated by {v} (Compound) Ezetimibe
Dicoumarol {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Warfarin
Warfarin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ezetimibe
Dicoumarol (Compound) resembles Warfarin (Compound) and Warfarin may cause a minor interaction that can limit clinical effects when taken with Ezetimibe
Dicoumarol (Compound) resembles Phenprocoumon (Compound) and Phenprocoumon (Compound) resembles Warfarin (Compound) and Warfarin may cause a minor interaction that can limit clinical effects when taken with Ezetimibe
Dicoumarol (Compound) resembles Warfarin (Compound) and Warfarin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ezetimibe (Compound)
Dicoumarol (Compound) resembles Warfarin (Compound) and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Ezetimibe
Dicoumarol (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Simvastatin (Compound) and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Ezetimibe
Dicoumarol (Compound) binds NQO1 (Gene) and NQO1 (Gene) regulates TM9SF3 (Gene) and TM9SF3 (Gene) is downregulated by Ezetimibe (Compound)
Dicoumarol (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Flunarizine (Compound) and Flunarizine (Compound) resembles Ezetimibe (Compound)
Dicoumarol (Compound) resembles Acenocoumarol (Compound) and Acenocoumarol (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Ezetimibe (Compound)
Dicoumarol (Compound) binds NQO1 (Gene) and NQO1 (Gene) regulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Ezetimibe (Compound)
Dicoumarol (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Warfarin (Compound) and Warfarin may cause a minor interaction that can limit clinical effects when taken with Ezetimibe